Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 482

1.

Combination antiangiogenic therapy and radiation in head and neck cancers.

Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, Mirshahidi S.

Oral Oncol. 2014 Jan;50(1):19-26. doi: 10.1016/j.oraloncology.2013.10.003. Epub 2013 Oct 23. Review.

PMID:
24269532
2.
3.

Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.

Gacche RN, Meshram RJ.

Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24139944
4.

Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Schultz JD, Mühlheim K, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.

Oncol Rep. 2011 Nov;26(5):1099-109. doi: 10.3892/or.2011.1403. Epub 2011 Jul 26.

PMID:
21805039
5.

Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.

Horn D, Hess J, Freier K, Hoffmann J, Freudlsperger C.

Expert Opin Ther Targets. 2015 Jun;19(6):795-805. doi: 10.1517/14728222.2015.1012157. Epub 2015 Feb 5. Review.

PMID:
25652792
7.

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.

9.

Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Aderhold C, Umbreit C, Faber A, Sauter A, Sommer JU, Birk R, Erben P, Hofheinz RD, Stern-Straeter J, Hörmann K, Schultz JD.

Anticancer Res. 2013 May;33(5):1951-61.

PMID:
23645743
10.

Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.

Riedel F, Götte K, Hörmann K, Grandis JR.

Adv Otorhinolaryngol. 2005;62:103-20.

PMID:
15608422
11.

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.

Ning S, Laird D, Cherrington JM, Knox SJ.

Radiat Res. 2002 Jan;157(1):45-51.

PMID:
11754641
12.

Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Shintani S, Kiyota A, Mihara M, Sumida T, Kayahara H, Nakashiro K, Hamakawa H.

Am J Clin Oncol. 2003 Oct;26(5):e150-6.

PMID:
14528090
13.

Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.

Aderhold C, Faber A, Grobschmidt GM, Chakraborty A, Bockmayer A, Umbreit C, Birk R, Stern-Straeter J, Hörmann K, Schultz JD.

Anticancer Res. 2013 Dec;33(12):5385-93.

PMID:
24324073
14.

Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.

Gyanchandani R, Sano D, Ortega Alves MV, Klein JD, Knapick BA, Oh S, Myers JN, Kim S.

Oral Oncol. 2013 Aug;49(8):761-70. doi: 10.1016/j.oraloncology.2013.03.452. Epub 2013 Apr 24.

PMID:
23623402
15.

Integration of molecular targeted therapy with radiation in head and neck cancer.

Du Y, Peyser ND, Grandis JR.

Pharmacol Ther. 2014 Apr;142(1):88-98. doi: 10.1016/j.pharmthera.2013.11.007. Epub 2013 Nov 23. Review.

PMID:
24280066
16.

PET monitoring of therapy response in head and neck squamous cell carcinoma.

Schöder H, Fury M, Lee N, Kraus D.

J Nucl Med. 2009 May;50 Suppl 1:74S-88S. doi: 10.2967/jnumed.108.057208. Epub 2009 Apr 20. Review.

17.

Targeting angiogenesis in head and neck cancer.

Vassilakopoulou M, Psyrri A, Argiris A.

Oral Oncol. 2015 May;51(5):409-15. doi: 10.1016/j.oraloncology.2015.01.006. Epub 2015 Feb 10. Review.

PMID:
25680863
18.

Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma.

Chen Z, Xu XH.

Saudi Med J. 2015 Jun;36(6):659-64. doi: 10.15537/smj.2015.6.11460. Review.

19.

Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.

Le Tourneau C, Siu LL.

Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Review.

PMID:
18391623

Supplemental Content

Support Center